LeonaBio, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
LeonaBio, Inc. (LONA) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$2.22 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-14
- LeonaBio, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $1.14M.
- LeonaBio, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$3.36M.
- LeonaBio, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$10.96M.
- LeonaBio, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$207.00K, a 124.70% decline year-over-year.
- LeonaBio, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was -$21.34M.
- LeonaBio, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was -$5.75M, a 178.06% decline from fiscal 2023.
- LeonaBio, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $7.37M, a 250.64% increase from fiscal 2022.
- LeonaBio, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $2.10M, a 59.20% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$2.22M 10-Q · filed 2026-08-14 | -$13.18M derived: sum of 3 quarters · filed 2026-08-14 | -$13.39M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$3.36M 10-Q · filed 2026-05-07 | -$14.32M derived: sum of 2 quarters · filed 2026-05-07 | -$14.53M derived: sum of 3 quarters · filed 2026-05-07 | -$17.05M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$10.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$11.16M derived: sum of 2 quarters · filed 2026-03-31 | -$13.69M derived: sum of 3 quarters · filed 2026-08-14 | -$21.34M 10-K · filed 2026-03-31 |
| 2025-09-30 | -$207.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$2.73M derived: sum of 2 quarters · filed 2026-08-14 | -$10.39M 10-Q · filed 2025-11-06 | -$15.01M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$2.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$10.18M 10-Q · filed 2026-08-14 | -$14.81M derived: sum of 3 quarters · filed 2026-08-14 | -$13.97M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$7.66M 10-Q · filed 2026-05-07 | -$12.28M derived: sum of 2 quarters · filed 2026-05-07 | -$11.45M derived: sum of 3 quarters · filed 2026-05-07 | -$10.15M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$4.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$3.79M derived: sum of 2 quarters · filed 2026-03-31 | -$2.50M derived: sum of 3 quarters · filed 2026-03-31 | -$5.75M 10-K · filed 2026-03-31 |
| 2024-09-30 | $838.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.13M derived: sum of 2 quarters · filed 2025-11-06 | -$1.12M 10-Q · filed 2025-11-06 | -$915.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$1.96M 10-Q · filed 2025-08-07 | -$1.75M derived: sum of 3 quarters · filed 2025-08-07 | $5.20M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$3.25M 10-Q · filed 2025-05-09 | -$3.05M derived: sum of 2 quarters · filed 2025-05-09 | $3.90M derived: sum of 3 quarters · filed 2025-05-09 | $5.41M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $208.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $7.16M derived: sum of 2 quarters · filed 2025-02-27 | $8.66M derived: sum of 3 quarters · filed 2025-02-27 | $7.37M 10-K · filed 2025-02-27 |
| 2023-09-30 | $6.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $8.45M derived: sum of 2 quarters · filed 2024-11-07 | $7.16M 10-Q · filed 2024-11-07 | $8.32M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $210.00K 10-Q · filed 2024-08-01 | $1.37M derived: sum of 3 quarters · filed 2024-08-01 | $1.95M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | -$1.29M 10-Q · filed 2024-05-15 | -$135.00K derived: sum of 2 quarters · filed 2024-05-15 | $444.00K derived: sum of 3 quarters · filed 2024-05-15 | $645.00K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $1.74M derived: sum of 2 quarters · filed 2024-02-22 | $1.94M derived: sum of 3 quarters · filed 2024-02-22 | $2.10M 10-K · filed 2024-02-22 |
| 2022-09-30 | $579.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $780.00K derived: sum of 2 quarters · filed 2023-11-09 | $944.00K 10-Q · filed 2023-11-09 | $1.18M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $201.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $365.00K 10-Q · filed 2023-08-10 | $602.00K derived: sum of 3 quarters · filed 2023-08-10 | $2.20M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $164.00K 10-Q · filed 2023-05-11 | $401.00K derived: sum of 2 quarters · filed 2023-05-11 | $2.00M derived: sum of 3 quarters · filed 2023-05-11 | $5.69M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $237.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $1.83M derived: sum of 2 quarters · filed 2023-03-23 | $5.52M derived: sum of 3 quarters · filed 2023-03-23 | $5.15M 10-K · filed 2023-03-23 |
| 2021-09-30 | $1.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $5.29M derived: sum of 2 quarters · filed 2022-11-10 | $4.91M 10-Q · filed 2022-11-10 | $4.51M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $3.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $3.32M 10-Q · filed 2022-08-15 | $2.92M derived: sum of 3 quarters · filed 2022-08-15 | $5.37M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | -$374.00K 10-Q · filed 2022-05-12 | -$777.00K derived: sum of 2 quarters · filed 2022-05-12 | $1.68M derived: sum of 3 quarters · filed 2022-05-12 | $2.16M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$403.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $2.06M derived: sum of 2 quarters · filed 2022-03-28 | $2.54M derived: sum of 3 quarters · filed 2022-03-28 | $2.60M 10-K · filed 2022-03-28 |
| 2020-09-30 | $2.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $2.94M derived: sum of 2 quarters · filed 2021-11-10 | $3.00M 10-Q · filed 2021-11-10 | $2.78M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $483.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $546.00K 10-Q · filed 2021-08-16 | $320.00K derived: sum of 3 quarters · filed 2021-08-16 | |
| 2020-03-31 | $63.00K 10-Q · filed 2021-05-13 | -$163.00K derived: sum of 2 quarters · filed 2021-05-13 | ||
| 2019-12-31 | -$226.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $701.00K 10-K · filed 2021-03-25 | ||
| 2019-09-30 | $927.00K 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |